By Dean Seal

Hologic notched higher earnings and sales in its fiscal fourth quarter from robust demand across its product divisions.

The medical-technology company, which has agreed to be acquired by Blackstone and TPG, posted a profit of $187.3 million, or 83 cents a share, for the quarter ended Sept. 27, compared with $178.6 million, or 76 cents a share, in the same quarter a year earlier.

Stripping out one-time items, adjusted earnings were $1.13 a share. Analysts surveyed by FactSet had been expecting $1.10 a share.

Revenue rose 6.2% to $1.05 billion, ahead of analyst forecasts for $1.03 billion, according to FactSet.

Diagnostics revenue was up thanks to higher core U.S. molecular diagnostics sales, offsetting lower sales of Covid-19 assays and weaker sales in China. Its breast health division's revenue rose as well from strength in its interventional products. Surgical revenue climbed more than 10% from strong demand for its MyoSure and Fluent systems.

The company said last month that it would be bought for up to $18.3 billion in a deal that's expected to close in the first half of next year. It isn't providing guidance while the deal is pending.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

November 03, 2025 16:25 ET (21:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.